Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Precigen, Inc.NASDAQ: PGEN
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow dips below year-ago levels
Q2 FY2026 free cash flow of $18.2M (cash outflow) fell 8.7% year over year, behind the +66.0% change in trailing-twelve-month free cash flow. Sequentially, it fell 58.7% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Free cash flow amounted to 927.6% of revenue in FY2025, down 1028.0 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.7% toward the trailing-twelve-month pace of +66.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (89.83M) USD
- Year-over-year change
- -17.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (89.83M) | -17.0% |
| FY2024 | 2024-12-31 | (76.76M) | -12.1% |
| FY2023 | 2023-12-31 | (68.47M) | +2.1% |
| FY2022 | 2022-12-31 | (69.97M) | -11.0% |
| FY2021 | 2021-12-31 | (63.02M) | — |
Free Cash Flow vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 free cash flow of $115.83M is the 6th largest of the 8 companies compared; the peer median is $179.8M.
- Its year-over-year change of +66.0% is the 2nd highest of 8, against a peer median of -0.4%.
- Free cash flow amounts to 135.1% of revenue for PGEN, versus a peer median of 457.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $376.72M | +24.3% | -13.4% | 1496.6% | |
| LTM Mar 2026 | $363.63M | -4.6% | -3.3% | 550.2% | |
| LTM Mar 2026 | $236.4M | +171.9% | -19.0% | 269.2% | |
| LTM Mar 2026 | $179.8M | -15.6% | +0.7% | — | |
| LTM Mar 2026 | $141.09M | -34.5% | -3.0% | 364.6% | |
| LTM Jun 2026 | $115.83M | +66.0% | +8.7% | 135.1% | |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $58.78M | -0.4% | +10.3% | 130.4% | |
| Peer median (excluding PGEN) | $179.8M | -0.4% | -3.0% | 457.4% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| Deferred Income Tax | (167K) | (150K) | (479K) | (1.8M) | 0 |
| Stock-Based Compensation | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M |
| Change in Working Capital | (804K) | (35.7M) | 17.07M | 4.52M | 6.62M |
| Accounts Receivables | (6.56M) | (13.51M) | 12.23M | 414K | (3.2M) |
| Inventory | (1.9M) | 2.34M | 0 | 0 | (9.21M) |
| Accounts Payables | 420K | 379K | (2.42M) | 1.55M | 8.77M |
| Other Working Capital | 7.24M | (24.91M) | 7.26M | 2.56M | 10.26M |
| Other Non-Cash Items | 9.7M | (78.48M) | (4.17M) | 41.34M | 142.12M |
| Operating Cash Flow | (55.77M) | (65.05M) | (66.93M) | (68.17M) | (87.83M) |
| Capital Expenditures | (7.25M) | (4.92M) | (1.54M) | (8.58M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (174.22M) | 0 | (185.03M) | (187.21M) | (208.01M) |
| Sales of Investments | 100.17M | 68.44M | 183.38M | 175.02M | 208.47M |
| Other Investing Activities | 6.76M | 162.9M | 98K | 60K | 0 |
| Investing Cash Flow | (74.54M) | 226.42M | (3.09M) | (20.71M) | (1.54M) |
| Debt Repayment | (466K) | (155.29M) | (43.22M) | 0 | 92.82M |
| Common Stock Issued | 121.05M | 0 | 72.81M | 31.24M | 310K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 608K | 1K | 0 | 346K | (3.08M) |
| Financing Cash Flow | 121.19M | (155.29M) | 29.59M | 110.58M | 90.05M |
| Effect of Forex Changes | 217K | (827K) | (320K) | (27K) | 35K |
| Net Change in Cash | (8.91M) | 5.25M | (40.75M) | 21.67M | 717K |
| Free Cash Flow | (63.02M) | (69.97M) | (68.47M) | (76.76M) | (89.83M) |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.